Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. - Wikidata - wikimedia - TriplyDB

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

http://www.wikidata.org/entity/Q42989510

about

Treatment of hepatitis C in children: a systematic review IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Boceprevir for previously treated chronic HCV genotype 1 infection Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes Site-Specific PEGylation of Therapeutic Proteins Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy Natural history and clinical response: "it's the virus, stupid, or is it the host?"Antiviral treatment of hepatitis C virus infection and factors affecting efficacy Emerging therapies for hepatitis C HIV and hepatitis C virus infection in the United States: whom and how to test Metabolic factors and chronic hepatitis C: a complex interplay Direct acting antivirals for the treatment of chronic viral hepatitis Hepatitis C virus: Promising discoveries and new treatments APRI as a predictor of early viral response in chronic hepatitis C patients Best strategies for global HCV eradication.Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users N-substituted benzyl matrinic acid derivatives inhibit hepatitis C virus (HCV) replication through down-regulating host heat-stress cognate 70 (Hsc70) expression Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3 An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C Boceprevir for untreated chronic HCV genotype 1 infection Pharmacokinetics of new oral hepatitis C antiviral drugs.An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin.Interleukin28B and inosine triphosphatase help to personalize hepatitis C treatment.

P2860

Q21136318-B9EDF550-A07E-4667-B00A-A1E7D5A800CC Q22121973-8D79F450-8BC6-4D2E-A387-036FEEAF7476 Q24200197-ECA53652-9184-40E2-953A-593FB0EC999E Q24200534-AB92D342-A2C9-4EFC-9D81-0CD21C9E0C5A Q24596340-2AED6B9A-733E-495C-BB7C-587A1FBDA859 Q24620576-2F964DAB-8344-493D-85CD-963F5408D38A Q26746563-BF217FC6-D1B2-4E52-A11C-332ACBB9726E Q26773187-EA38DF82-23E9-4234-91ED-DF2C3854DB0A Q26773283-42B30297-C3C7-48F3-8C83-CE9A219156AB Q26774517-58ACE85D-E388-4E17-9CC1-A56CE314EB74 Q26777086-97C143B4-7EF9-4093-B108-D07A15DCA52D Q26777819-8824FAF4-FF0C-44A4-ABAD-561613F0353A Q26781481-EEE8C841-816D-4EF1-90F4-EB4C9EB4CB88 Q26824094-58390C98-A869-45AB-8DBF-14147602F696 Q26851810-1ACA41D6-E3D1-4F85-8953-B5DB0849C09F Q26853642-F73756F0-005D-4F67-A56D-D54EF26E2CEA Q26996736-BAF338AF-A476-455F-9D5D-63F91DC7E1B1 Q27011787-609A5A53-E122-4A13-96A4-F3502F96A226 Q27022216-7B683054-6E7E-4454-9214-7B61EE3870FA Q27468916-05C7F2CC-DBDA-430C-B6DA-966872B11D2D Q27490204-28AE5957-8254-4E89-8D56-C1D310F00382 Q27693824-28324C47-0AE5-4EF7-B976-06A656F01599 Q28080225-8C1E8B44-00DB-4497-A5BE-5EC8CD54A59D Q28255239-B9F28FAB-EC23-4BD0-9A6B-D88F016D2B66 Q28281519-78FFD2F4-821E-4B10-BAE2-E84803C110C6 Q28481038-91A4654F-197F-4ABA-A263-8F05D2F9E62A Q28483820-8F78A7E5-DB90-4DC3-98DC-A12A8722C7B7 Q28488041-729B6408-DF2F-4BBB-B4CC-86AC57E9FD0D Q28488762-C1A59760-B1FC-437E-8BB4-CF0C6CAFC85C Q28729225-59FDD38E-4F9E-4A4C-8606-06E8320EF2E9 Q28742764-A18B947D-C89D-4F7E-A9B3-A052B88CC6BF Q29620617-5F04BC7C-F387-4FD0-B876-6421E158A36D Q30422746-69B616A2-F4F5-4445-8FE2-2A7113BD1166 Q30453975-3EE8952F-CC9E-4D62-AB5E-823684BC0A8C Q31076943-2DC5EB1D-A08D-45AB-80BB-FE220280E94D Q33392904-9381E56C-C0B9-4EAE-BA7C-22709D4E046D Q33394544-F06E0FF1-3AE0-4753-89F8-EB850439FB0B Q33395929-20A57095-28AA-41DF-B789-345D448F0F4F Q33398403-03EDB5B6-F2E0-4A15-9350-10672B995322 Q33398664-E5701652-D5FD-4E2D-AD51-A0002C1AC0F6

P2860

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

http://www.wikidata.org/entity/Q42989510

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

@en

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

@nl

type

label

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

@en

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

@nl

prefLabel

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

@en

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

@nl

P1433

Q42989510-1D0E3AEF-DEA5-44A1-9201-5E932A7153DF

P1476

Q42989510-F9F7BB5F-EF4F-4C68-8A03-0B73F07B3478

P2093

Q42989510-025819E2-71FF-40A0-B114-90C1A059ABAC

Q42989510-08996BA5-462D-4D9B-BA92-74BE7438035C

Q42989510-0BD417A6-C31D-4DD7-B35B-8CFF349AC84F

Q42989510-2FDC9BC4-562D-436A-ACB6-F397F0CE5B3E

Q42989510-325C7228-0E8A-49C1-A307-9D2D55FCD171

Q42989510-54E5AB39-C7DB-4E31-AC09-FB686D9827E1

Q42989510-68F5D474-B0DA-4BC5-B62A-FEBFDCD144F4

Q42989510-6FB32772-BC2D-4F5A-AEED-92848B006B07

Q42989510-7C68818E-96CC-4098-95B6-9A57E115BA02

Q42989510-885FEF15-CE9F-4C1E-BB00-6ECB9D2E3A90

P304

Q42989510-F9B8AC8B-0BD1-4BF1-836B-23A53F3AB227

P31

Q42989510-7082B70B-5DFA-497D-AAFA-C189419BFD1B

P356

Q42989510-5B6BF20F-73DB-4B23-9144-42687AC1DB3B

P407

Q42989510-1AFE4D07-76E8-4234-8B29-F4A5AA18AA42

P433

Q42989510-80537692-CDD1-4425-B043-BC4FF3393AE2

P478

Q42989510-C99D73FB-0220-4768-8476-B0AFDBE3AC3B

P50

Q42989510-EB6164A2-0BDF-49F6-9089-9D80F53614E1

P577

Q42989510-76D81918-B56D-415C-871E-132601EB018C

P698

Q42989510-0562C1E5-63ED-4AB3-BABE-F0CD43C44086

P356

P1433

The New England Journal of Medicine

P1476

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

@en

P2093

Andrew J Muir

http://www.w3.org/2001/XMLSchema#string

Bruce R Bacon

http://www.w3.org/2001/XMLSchema#string

Clifford A Brass

http://www.w3.org/2001/XMLSchema#string

Eric J Lawitz

http://www.w3.org/2001/XMLSchema#string

Eugene R Schiff

http://www.w3.org/2001/XMLSchema#string

Greg W Galler

http://www.w3.org/2001/XMLSchema#string

IDEAL Study Team

http://www.w3.org/2001/XMLSchema#string

Janice K Albrecht

http://www.w3.org/2001/XMLSchema#string

John G McHutchison

http://www.w3.org/2001/XMLSchema#string

Jonathan McCone

http://www.w3.org/2001/XMLSchema#string

P304

580-593

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0808010

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

361

http://www.w3.org/2001/XMLSchema#string

P50

Mitchell N Davis

P577

2009-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19625712

http://www.w3.org/2001/XMLSchema#string